Abstract
ACC/AHA 2013 guidelines for atherosclerotic cardiovascular disease (ASCVD) recommend use of statins to achieve 30 to ≥50% reduction in LDL-C. We assessed the relationship of additional LDL-C % reduction and ASCVD event rates in patients (most on maximally tolerated statins ± ezetimibe [EZE] at
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
